{
  "pmid": "40048065",
  "title": "Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.",
  "abstract": "",
  "pub_date": "2025-04",
  "publication_types": [
    "Published Erratum"
  ],
  "affiliations": [
    "Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.",
    "Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.",
    "Clinical Outcomes Solutions, Tucson, AZ, USA.",
    "Clinical Outcomes Solutions, Tucson, AZ, USA.",
    "Clinical Outcomes Solutions, Tucson, AZ, USA.",
    "Medical College of Wisconsin, Milwaukee, WI, USA.",
    "Bristol Myers Squibb, 3401 Princeton Pike, Princeton, NJ, 08648, USA. joe.zhuo@bms.com.",
    "Bristol Myers Squibb, 3401 Princeton Pike, Princeton, NJ, 08648, USA.",
    "Bristol Myers Squibb, 3401 Princeton Pike, Princeton, NJ, 08648, USA.",
    "Bristol Myers Squibb, 3401 Princeton Pike, Princeton, NJ, 08648, USA.",
    "Bristol Myers Squibb, 3401 Princeton Pike, Princeton, NJ, 08648, USA.",
    "Alliance Clinical Trials and Probity Medical Research, Waterloo, ON, Canada.",
    "University of Toronto, Toronto, ON, Canada."
  ],
  "url": "https://pubmed.ncbi.nlm.nih.gov/40048065/",
  "snapshot_id": "2026-02-12T14-08-00Z",
  "ingested_at": "2026-02-12T14:08:04.327151+00:00"
}